A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Condition:   Multiple Sclerosis, Primary Progressive
Interventions:   Drug: Ocrelizumab;   Other: Placebo
Sponsor:   Hoffmann-La Roche
Active, not recruiting